RxDoctor Payments Data

Matthew Powell, DO

Family Medicine · Muskegon, MINPI 1154316222

Payments from drug & device makers

$10,552in general payments, 2019–2025

Across 697 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • GSK$806
  • Boehringer Ingelheim$761
  • Pfizer$702
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,522100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,552 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$71,901
Medicare patients
106
Services billed
1,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$168,012
EliquisApixaban128$127,819
JardianceEmpagliflozin105$121,331
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$104,083
OtezlaApremilast21$96,877
HumiraAdalimumab12$85,217
TrulicityDulaglutide46$58,403
FarxigaDapagliflozin Propanediol24$26,800
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen986$20,318
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid139$19,089
XareltoRivaroxaban18$18,858
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$16,436
MounjaroTirzepatide15$14,620
MyrbetriqMirabegron11$11,705
Spiriva RespimatTiotropium Bromide11$11,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,748$168,012136 claims
Boehringer IngelheimJardiance, Spiriva Respimat$761$132,554116 claims
PfizerEliquis$702$127,819128 claims
GSKTrelegy Ellipta, Anoro Ellipta$806$110,813129 claims
AmgenOtezla$667$96,87721 claims
AbbVieHumira$1,584$85,21712 claims
Lilly USA, LLCTrulicity, Mounjaro$635$73,02261 claims
AstraZenecaFarxiga$1,043$26,80024 claims
Johnson & JohnsonXarelto$231$18,85818 claims
Astellas Pharma US IncMyrbetriq$64$11,70511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →